A proportion of people infected with SARS-CoV-2 develop moderate or severe COVID-19,
with an increased risk of thromboembolic complications. The inflammatory response to …

COVID-19 is associated with a high incidence of thrombotic complications, which can be
explained by the complex and unique interplay between coronaviruses and endothelial …

Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has been associated with
coagulation dysfunction which predisposes patients to an increased risk of both venous and …

A high incidence of thrombosis in hospitalised patients with COVID-19 was identified early
during the pandemic. Accurately quantifying thrombotic risk may assist prognosis and guide …

The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening
multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with …

Emerging evidence shows that severe coronavirus disease 2019 (COVID‐19) can be
complicated with coagulopathy, namely disseminated intravascular coagulation, which has …

The coagulopathy caused by SARS-CoV-2 seen in patients hospitalised with COVID-19,
especially those with severe or critical illness, is by now well established. Early reports in …

Abstract Corona virus 2 (SARS-CoV2/Severe Acute Respiratory Syndrome Corona Virus 2)
infection has emerged as a global health crisis. Incidence of thromboembolic disease is …

The SARS-CoV-2 virus caused a global pandemic within weeks, causing hundreds of
thousands of people infected. Many patients with severe COVID-19 present with coagulation …

Early in the COVID-19 pandemic, it became clear that coagulopathy leading to
macrovascular and microvascular thrombotic events was a considerable potential …